Richard Furman, MD, is the director of the CLL Research Center and a professor of medicine at Weill Cornell Medicine, New York City, New York.
Dr Furman received his medical degree in 1993 from Mount Sinai School of Medicine. In 2004, he joined Weill Cornell Medicine as an assistant professor of medicine. Since then, Dr Furnman has specialized in hematological oncology.
Speaking on CLL, Waldenstrom’s macroglobulinemia and novel treatments
Dr Furman’s main areas of interest are focused on the development of novel non-chemotherapeutic drugs. Dr Furman has played a key role in the development of ibrutinib and idelalisib for treating chronic lymphocytic leukemia (CLL). He is also an active member of the Lymphoma and Myeloma Service at Weill Cornell Medicine, New York City, New York.